Welcome to the CEO Roundtable on Cancer Web Site.


The mission of the CEO Roundtable on Cancer is to make continual progress toward the elimination of cancer as a personal disease and public health problem. Members of the CEO Roundtable collaboratively work to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate better access to best-available treatments, and hasten the discovery of novel and more effective diagnostic tools and anti-cancer therapies.


Message from the Chairman, CEO Roundtable on Cancer
Robert A. Bradway, Chairman and CEO, Amgen

Through the CEO Roundtable on Cancer, leaders from industry, academia and the public sector have the opportunity to collaborate to enhance cancer prevention and treatment, and to foster research on behalf of cancer patients. Our hope is that powerful initiatives like the CEO Gold Standard accreditation and Project Data Sphere, LLC, will facilitate better access to the best-available treatments, advance research and ultimately, save lives.
Learn more about the
  • Robert A. BradwayRobert A. Bradway
  • Christopher A. ViehbacherChristopher A. Viehbacher
  • William C. WeldonWilliam C. Weldon
  • Robert A. IngramRobert A. Ingram
  • Martin J. Murphy, DMedSc, PhD, FASCOMartin J. Murphy, DMedSc, PhD, FASCO
  • Mimi Hancock, PhDMimi Hancock, PhD
  • Gregory A. Curt, M.D.Gregory A. Curt, M.D.
  • Mace Rothenberg, M.D.Mace Rothenberg, M.D.
  • Judy OJudy O
  • Fikry W. Isaac, MD, MPH, FACOEMFikry W. Isaac, MD, MPH, FACOEM
  • John N. DornanJohn N. Dornan

The Gold Standard is a workplace-based program that focuses on lowering the risk of cancer, detecting it early when outcomes are more likely to be favorable, and ensuring access to quality care. Visit Website

The Life Sciences Consortium (LSC) brings together oncology pharmaceutical / biotechnology companies who work to remove roadblocks and find new ways to accelerate discovery and development of new therapies for all cancer patients. Visit Website

The Project Data Sphere platform provides one place where the research community can broadly share, integrate and analyze historical, patient-level, comparator-arm data from academic and industry phase III cancer clinical trials. Visit Website